Arctic Therapeutics closes €26.5m Series A for clinical development
The Icelandic company funds dementia and inflammatory skin-disease programmes.
Arctic Therapeutics announced a €26.5 million Series A on 22 January 2025. The investor group included the EIC Fund, Kaldbakur, Sanos Group, Cerebrum DAO and The Lurie Family Foundation, alongside a consortium of early investors and family offices.
The proceeds were allocated to advancing AT-001 and AT-004 in clinical development. AT-001 targets rare forms of dementia, while AT-004 is being developed for inflammatory skin diseases.
Sanos Group CEO Jeppe Ragnar Andersen joined the board. The company planned to draw on Sanos’ experience in dermatology and Alzheimer’s clinical research as it developed its investigational treatments.
Use of funds
Advance AT-001 and AT-004 clinical development